Cargando…

IDH1 mutation analysis – an example of putative glioma marker

Detalles Bibliográficos
Autores principales:	Lewandowska, Marzena, Szylberg, T, Roszkowski, K, Furtak, J, Windorbska, W, Rytlewska, J, Jóźwicki, W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395401/ http://dx.doi.org/10.1186/1897-4287-10-S3-A14

Ejemplares similares

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions
por: Roszkowski, Krzysztof, et al.
Publicado: (2016)

Expression of Oct4A splicing variant in human bladder premalignant lesions predicts its invasiveness
por: Jóźwicki, Wojciech, et al.
Publicado: (2012)

Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients
por: Roszkowski, Krzysztof, et al.
Publicado: (2014)

MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS
por: Wakabayashi, Hikaru, et al.
Publicado: (2019)

Prognostic and Predictive Biomarkers in Gliomas
por: Śledzińska, Paulina, et al.
Publicado: (2021)

KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

NI-13 THE RATIO OF T1-WEIGHTED TO T2-WEIGHTED SIGNAL INTENSITY AND IDH MUTATION IN GLIOMA
por: Sanada, Takahiro, et al.
Publicado: (2022)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
por: Arita, Hideyuki, et al.
Publicado: (2019)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
por: Sanada, Takahiro, et al.
Publicado: (2021)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients
por: LEWANDOWSKA, MARZENA ANNA, et al.
Publicado: (2013)

Expression of the HBZ and tax genes of HTLV-1in infective dermatitis associated with HTLV-I (IDH)
por: Batista, Everton S, et al.
Publicado: (2011)

Integration sites of the HTLV-1 provirus in host human genome in the IDH patients with monoclonal integration
por: Argolo, Juliana M, et al.
Publicado: (2011)

The spectrum of mutations in families with breast and ovarian cancer from the region of Saxony, Germany
por: Tomys, Michalina, et al.
Publicado: (2015)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

The p78 Putative Rheumatoid Arthritis T Cell Autoantigen
por: Panayi, GS, et al.
Publicado: (2000)

IDH1 Mutation in Gliomas in Mosul City - Iraq
por: Saeed, Mohammed Sami
Publicado: (2015)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
por: Jalbert, Llewellyn E., et al.
Publicado: (2017)

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
por: Han, Sue, et al.
Publicado: (2020)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

CS-12 IDH-1 MUTANT GLIOMA IN BROTHER AND SISTER, ONSET AT AGE OF 30s
por: Kitai, Ryuhei, et al.
Publicado: (2019)

Glioma Biopsy Based on Hybrid Dual Time-Point FET-PET/MRI—A Proof of Concept Study
por: Furtak, Jacek, et al.
Publicado: (2021)

Peripheral Inflammatory Blood Markers in Diagnosis of Glioma and IDH Status
por: Sharma, Gaurav, et al.
Publicado: (2021)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

ABC transporters of Fasciola hepatica as putative drug targets
por: El-Kasaby, Ali, et al.
Publicado: (2011)

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas
por: Duan, Wen-chao, et al.
Publicado: (2018)

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
por: Mortazavi, Armin, et al.
Publicado: (2021)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Migration of dendritic cells into the lymphatics: the Langerhans cell example
por: Romani, N, et al.
Publicado: (2003)

Lysosomal storage disorders for the pediatric rheumatologist: the example of mucopolysaccharydoses
por: Cimaz, Rolando, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iufilthr7ld5dclqgtc39k252u